Hepatitis

PubMed Free Full Text

Hepatitis C: treatment

Albania

• Virology Journal
  • Treatment and follow up of children with chronic hepatitis C in Albania [2012]

Asia-Pacific

• Asian Pacific Association for the Study of the Liver
  • APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? [2019]
  • APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation [2019]
  • APASL consensus statements and recommendation on treatment of hepatitis C [2016]

• Journal of Virus Eradication
  • The hepatitis C treatment revolution: how to avoid Asia missing out [2015]

Australia

• Australian Family Physician
  • A practical overview of the treatment of chronic hepatitis C virus infection [2016]

• Australian Journal of General Practice
  • Hepatitis C direct-acting antiviral treatment completion: Comparison of geographic, demographic and clinical characteristics in Australia [2023]
  • Treating chronic hepatitis C in general practice [2021]
  • Insights into the management of chronic hepatitis C [2018]

• Australian Prescriber
  • Treating hepatitis C – what’s new? [2015]

• BMC Gastroenterology
  • Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up [2022]

• ClinicoEconomics and Outcomes Research
  • The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia [2017]

• Drug and Alcohol Review
  • Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C) [2024]

• Gastroenterological Society of Australia
  • Goal of treatment of chronic hepatitis C [2022]

• Hepatology Communications
  • Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021 [2023]

• PLoS ONE
  • Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis [2021]

Australia, New Zealand

• Australasian Hepatology Association
  • The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals [2016]

• Royal Australian and New Zealand College of Psychiatrists
  • Treating hepatitis C [2022]

Brazil

• BMC Public Health
  • The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy [2016]

• Brazilian Journal of Infectious Diseases
  • National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents [2022]
  • Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil [2018]

• Ciência & Saúde Coletiva
  • Public procurement of hepatitis C medicines in Brazil from 2005 to 2015 [2017]

• Cost Effectiveness and Resource Allocation
  • Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil [2013]

• Revista da Sociedade Brasileira de Medicina Tropical
  • Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil [2020]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection [2023]
  • Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence [2015]
  • Triple Therapy for Hepatitis C in Previous Non-responders: A Review of the Clinical Effectiveness and Safety [2014]
  • Treatments for Patients with Genotype 1 Chronic Hepatitis C: A Review of Evidence-based Guidelines [2014]
  • Interferon-free Regimens for Genotype 1 Chronic Hepatitis C: A Review of the Clinical Evidence and Cost-Effectiveness [2014]

• Canadian Association for the Study of the Liver
  • The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver [2018]
  • An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver [2015]

• Canadian Journal of Gastroenterology & Hepatology
  • Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: A policy statement and implementation guideline [2014]

• CanHepC - Canadian Network on Hepatitis C
  • Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C [2018]
  • Remaining clinical issues in hepatitis C treatment [2018]
  • Can we afford not to screen and treat hepatitis C virus infection in Canada? [2018]
  • Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study [2016]

• CMAJ Open
  • Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis [2017]

• JAMA Network Open
  • Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model [2020]

• Journal of Viral Hepatitis
  • Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis [2024]

• PLoS ONE
  • Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? [2015]

• Public Health Agency of Canada
  • Hepatitis C treatment trends in Canada

China

• BMJ Global Health
  • Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective [2020]

• International Journal of Environmental Research and Public Health
  • Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China [2020]

• Journal of Clinical and Translational Hepatology
  • Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China [2021]

• PLoS ONE
  • Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data [2016]

• World Journal of Gastroenterology
  • Current treatment of chronic hepatitis C in China: Dilemma and potential problems [2016]

Colombia

• Pharmacology Research & Perspectives
  • Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE [2019]

Egypt

• Alimentary Pharmacology & Therapeutics
  • Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies [2015]

Europe

• BMC Infectious Diseases
  • Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries [2014]
  • A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region [2014]

• BMC Public Health
  • Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe [2019]

• European Association for the Study of the Liver
  • EASL position paper on clinical follow-up after HCV cure [2024]
  • EASL recommendations on treatment of hepatitis C: Final update of the series [2020]
  • EASL Recommendations on Treatment of Hepatitis C 2018 [2018]
  • Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015 [2015]

• Frontiers in Pharmacology
  • Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future [2016]

• Harm Reduction Journal
  • Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries [2019]

• Liver International
  • The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries [2021]

France

• BMC Infectious Diseases
  • Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015 [2017]

Germany

• BMC Infectious Diseases
  • Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach [2015]

• BMJ Open Gastroenterology
  • Economic study of the value of expanding HCV treatment capacity in Germany [2017]

• Institute for Quality and Efficiency in Health Care
  • Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V [2019]
  • Elbasvir/grazoprevir (chronic hepatitis C) - Benefit assessment according to §35a Social Code Book V [2017]

• International Journal of Environmental Research and Public Health
  • Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany [2020]

• PLoS ONE
  • Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results [2020]
  • Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany [2017]
  • Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study [2016]

• Visceral Medicine
  • The New Era of Interferon-Free Treatment of Chronic Hepatitis C [2015]

High-income countries

• BMC Primary Care
  • Prescribing direct-acting antivirals for hepatitis C treatment: a scoping review of factors that influence primary care providers [2025]

Iceland

• Clinical Infectious Diseases
  • High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study [2022]

• International Journal of Drug Policy
  • Predictors of treatment outcomes for Hepatitis C infection in a nationwide elimination program in Iceland: The treatment as prevention for Hepatitis C (TraP HepC) study [2024]

India

• Journal of Clinical and Experimental Hepatology
  • Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015 [2015]

International

• Autoimmune Diseases
  • International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement [2017]

• Ciência & Saúde Coletiva
  • Factors associated with hepatitis C treatment adherence: an integrative review [2022]

• Clinical Pharmacology & Therapeutics
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-a–Based Regimens [2014]

• EClinicalMedicine
  • Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis [2020]

• European Society for Paediatric Gastroenterology Hepatology and Nutrition
  • ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings [2024]

• Journal of Clinical Pharmacy and Therapeutics
  • Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis [2022]

• PLoS Medicine
  • Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis [2016]

• Scientific Reports
  • Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data [2016]

Israel

• Health Care Management Science
  • Country versus pharmaceutical company interests for hepatitis C treatment [2022]

Italy

• ClinicoEconomics and Outcomes Research
  • Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service [2017]
  • Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives [2016]

• Digestive and Liver Disease
  • Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) [2013]

• International Journal of Environmental Research and Public Health
  • Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study [2021]

• Journal of Viral Hepatitis
  • Long-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy [2025]

Japan

• Drug Design, Development and Therapy
  • Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study [2016]

• Journal of Gastroenterology
  • Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines [2013]

• Scientific Reports
  • Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies [2023]

• Viruses
  • HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy [2015]

• World Journal of Hepatology
  • Natural interferon-beta treatment for patients with chronic hepatitis C in Japan [2015]

Low and middle income countries

• Clinical Infectious Diseases
  • Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries [2022]

• International Journal of Environmental Research and Public Health
  • Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis [2020]

• World Health Organization
  • Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries [2018]

Mexico

• Viruses
  • Hepatitis C Virus Resistance-Associated Substitutions in Mexico [2025]

Mongolia

• Viruses
  • Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia [2025]

Netherlands

• European Journal of Internal Medicine
  • Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination [2022]

• PLoS ONE
  • Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study [2016]

Norway

• BMJ Open
  • On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017 [2020]

• EuroSurveillance
  • Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: a registry-based study to monitor progress towards elimination [2024]

Pakistan

• Asian Pacific Journal of Tropical Medicine
  • Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective [2015]

• BMJ Open
  • Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections [2019]

Poland

• Clinical and Experimental Hepatology
  • Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020 [2020]
  • Recommendations for the treatment of hepatitis C in 2017 [2017]
  • Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study [2016]

• Przeglad Epidemiologiczny - Epidemiological Review
  • Recommendations for the treatment of hepatitis C Polish group of HCV Experts--2015 [2015]
  • Standards of hepatitis C treatment. Recommendations of Polish Group of Experts--2014 [2014]

Republic of Korea

• Clinical and Molecular Hepatology
  • Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL [2018]

• Korean Association for the Study of the Liver
  • 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C [2018]

Saudi Arabia

• Saudi Journal of Gastroenterology
  • SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024 [2024]

Spain

• Health Policy
  • The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain - Health Policy [2016]

Sub-Saharan Africa

• BMC Health Services Research
  • Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa [2022]

Sweden

• Infectious Diseases
  • Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations [2015]

Switzerland

• PLoS ONE
  • Drug Pricing Evolution in Hepatitis C [2016]
  • Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C [2015]

• Swiss Medical Weekly
  • Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis [2024]
  • Hepatitis C virus elimination in Swiss opioid agonist therapy programmes – the SAMMSU cohort [2021]

Taiwan

• Hepatology International
  • An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan [2024]
  • Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry [2023]

• Journal of the Formosan Medical Association
  • Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan [2022]
  • 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population [2020]
  • 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations [2020]

• Medicine
  • Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C [2015]

Thailand

• BMC Gastroenterology
  • Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6 [2016]

• PLoS ONE
  • Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era [2016]

Turkey

• Balkan Medical Journal
  • Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study [2016]

• Turkish Journal of Gastroenterology
  • Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey [2022]
  • Recommendation for treatment of hepatitis C virus infection [2017]

United Kingdom

• Alimentary Pharmacology & Therapeutics
  • 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy [2014]

• Journal of Infection
  • Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England [2025]

• Medicines and Healthcare products Regulatory Agency
  • Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR [2017]
  • Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation [2017]

• National Institute for Health and Care Excellence
  • Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C [2018]
  • Glecaprevir–pibrentasvir for treating chronic hepatitis C [2018]
  • Sofosbuvir–velpatasvir for treating chronic hepatitis C [2017]
  • Elbasvir–grazoprevir for treating chronic hepatitis C [2016]
  • Sofosbuvir for treating chronic hepatitis C [2015]
  • Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C [2015]
  • Ledipasvir–sofosbuvir for treating chronic hepatitis C [2015]
  • Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people [2013]
  • Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C [2010]

• NHS England
  • Antivirals for adults with recent onset (acute) hepatitis C [2019]
  • Treatment of chronic Hepatitis C in patients with cirrhosis [2015]

• PLoS ONE
  • Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections [2015]

United States

• Agency for Healthcare Research and Quality
  • Treatment for Hepatitis C Virus Infection in Adults [2012]
  • Comparative Effectiveness of Treatments for Chronic Hepatitis C Virus Infection in Adults [2012]

• American Association for the Study of Liver Diseases
  • An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases [2011]
  • Retreatment of Persons in Whom Prior Therapy Failed
  • Initial Treatment of HCV Infection

• American College of Physicians
  • World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians [2021]

• American Gastroenterological Association
  • AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review [2020]
  • American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection [2017]

• American Journal of Managed Care
  • Costs and Spillover Effects of Private Insurers’ Coverage of Hepatitis C Treatment [2016]
  • Accessing the Cure: Helping Patients With Hepatitis C Overcome Barriers to Care [2016]

• BMC Gastroenterology
  • Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US [2015]

• Centers for Disease Control and Prevention
  • Vital Signs: Hepatitis C Treatment Among Insured Adults — United States, 2019–2020 [2022]
  • Too Few People Treated for Hepatitis C
  • Clinical Care of Hepatitis C

• Expert Review of Pharmacoeconomics & Outcomes Research
  • Cost effectiveness of hepatitis C direct acting agents [2024]

• Hepatitis C Online
  • Treatment of Key Populations and Unique Situations
  • Treatment of Hepatitis C Infection
  • Medications to Treat HCV
  • Evaluation and Preparation for Hepatitis C Treatment

• Infectious Agents and Cancer
  • Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States [2016]

• Infectious Diseases and Therapy
  • Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need [2016]

• JAMA Network Open
  • Medicaid Expansion and Restriction Policies for Hepatitis C Treatment [2024]

• Journal of Managed Care & Specialty Pharmacy
  • Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective [2022]

• Liver International
  • HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape [2015]

• Open Forum Infectious Diseases
  • The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets [2018]

• Pediatrics
  • Disparities in Linkage to Care Among Children With Hepatitis C Virus in the United States [2025]

• PLoS ONE
  • Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries [2022]
  • The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis [2014]

Western countries

• International Journal of Drug Policy
  • Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation [2022]

• Substance Abuse Treatment, Prevention, and Policy
  • Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world [2022]

WHO

• World Health Organization
  • Updated recommendations on treatment of adolescents and children with chronic HCV infection [2022]

{Related topics}

• Topic
  • Hepatitis C